Diverse stage-dependent effects of glucocorticoids in a murine model of viral myocarditis
Related Experiment Video
Updated: May 14, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Hiroshi Nakamura1, Ichiro Kunitsugu, Keiichi Fukuda
1Department of Community Health and Medicine, Yamaguchi University Graduate School of Medicine, Ube, Japan. nahirosi@yamaguchi-u.ac.jp
Background:
The effects of glucocorticoids on viral myocarditis are contentious. The aim of the present study was to determine whether there is a "window of opportunity" for glucocorticoid treatment in a mouse model of acute viral myocarditis induced by Coxsackie group B3 virus (CVB3).
Methods:
A/J (H-2a) mice were randomly assigned to one of four experimental groups: (1) viral infection without dexamethasone (DEX) treatment; (2) treatment with 0.75mg/kg, i.p., DEX each day for 5 days prior to viral infection; (3) 0.75mg/kg, i.p., DEX treatment for 5 days immediately after viral infection; and (4) 0.75mg/kg, i.p., DEX treatment for 5 days starting on day 7 after infection.
Results:
DEX administration before or immediately after viral infection improved survival and attenuated left ventricular dilatation, systolic dysfunction, fibrosis, and infiltration of immune cells in the post-infectious heart. In contrast, late administration of DEX reduced survival (as determined on day 14), and was associated with sustained increases in cardiac tumor necrosis factor-α and interferon-γ levels. The beneficial effects of early DEX administration on survival were completely abrogated by coadministration of a selective cyclooxygenase (COX)-2 inhibitor (NS-398; 5mg/kg per day, p.o.). Notably, the virus titer in the post-infectious heart was significantly suppressed by DEX, but coadministration of NS-398 at the time of viral infection abolished the suppressive effects of DEX and, in fact, increased virus titers.
Conclusions:
Early administration of DEX is beneficial in the treatment of fulminant viral myocarditis, whereas late administration of DEX is harmful. The beneficial effects of DEX on survival were completely abolished by simultaneous administration of a selective COX-2 inhibitor. Hence, we speculate that a direct action of DEX on cardiomyocytes, rather than anti-inflammatory effects of DEX on immune cells, confers resistance to myocardial damage induced by viral infection.
Insights
Early dexamethasone (DEX) treatment improves survival in viral myocarditis. Late DEX is harmful and its benefits are blocked by COX-2 inhibitors, suggesting a direct effect on heart cells.
Area of Science:
- Cardiology
- Virology
- Immunology
Background:
- The role of glucocorticoids in viral myocarditis remains debated.
- Acute viral myocarditis, often caused by Coxsackie B3 virus (CVB3), presents a significant clinical challenge.
Purpose of the Study:
- To investigate the therapeutic window for glucocorticoid (dexamethasone) treatment in a mouse model of acute viral myocarditis.
- To elucidate the mechanisms underlying the effects of dexamethasone on viral myocarditis progression.
Main Methods:
- A/J mice were infected with CVB3 and treated with dexamethasone (DEX) at different time points: pre-infection, immediately post-infection, or 7 days post-infection.
- Survival rates, cardiac function, fibrosis, immune cell infiltration, and viral titers were assessed.
- The role of cyclooxygenase-2 (COX-2) was evaluated using a selective COX-2 inhibitor (NS-398).
Main Results:
- Early DEX administration (pre- or immediately post-infection) improved survival, attenuated cardiac dysfunction, and reduced inflammation and fibrosis.
- Late DEX administration (starting day 7 post-infection) decreased survival and increased pro-inflammatory cytokine levels (TNF-α, IFN-γ).
- The beneficial effects of early DEX were abolished by co-administration of a COX-2 inhibitor, which also increased viral titers.
Conclusions:
- Early dexamethasone treatment is beneficial in acute viral myocarditis, while late treatment is detrimental.
- The protective effects of early DEX are mediated, at least in part, through COX-2 inhibition.
- Dexamethasone may exert direct protective effects on cardiomyocytes, independent of its anti-inflammatory actions on immune cells.
Related Concept Videos
Myocarditis I: Introduction
Cardiomyopathy II: Dilated Cardiomyopathy
Myocarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis III: Medical Management
